When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.

Esteban Lopez Biography and Net Worth

Director of Axonics

Dr. López has served as a member of the Board since July 2021. Since January 2021, he has served on the Board of Directors of Addus HomeCare Corporation (NASDAQ: ADUS), a publicly traded provider of home care services, and is the founder and CEO of Hopscotch Health, a clinical practice focused on children's urgent care needs. From September 2020 to March 2023, he served as the Americas healthcare and life sciences Market Lead at Google Cloud with multinational executive responsibility for strategy and solutions development. From March 2013 to December 2019, he worked at Health Care Service Corporation (HCSC) in several executive roles, most recently as Chief Medical Officer for Clinical Strategy and Innovation. HCSC is the fourth largest health insurer in the U.S. Dr. López received a B.A. in biology from the University of California, Santa Cruz, his medical degree from Michigan State University College of Human Medicine, and his MBA from the University of Texas at Dallas. Dr. López is dual board certified in both internal medicine and pediatrics and continues to practice medicine in his free time at Hopscotch Health.

What is Esteban Lopez's net worth?: The estimated net worth of Esteban Lopez is at least $240,084.00 as of December 13th, 2022. Dr. Lopez owns 3,600 shares of Axonics stock worth more than $240,084 as of April 28th. This net worth evaluation does not reflect any other investments that Dr. Lopez may own. Learn More about Esteban Lopez's net worth.
How do I contact Esteban Lopez?: The corporate mailing address for Dr. Lopez and other Axonics executives is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. Axonics can also be reached via phone at (949) 396-6322 and via email at [email protected]. Learn More on Esteban Lopez's contact information.
Has Esteban Lopez been buying or selling shares of Axonics?: Esteban Lopez has not been actively trading shares of Axonics within the last three months. Most recently, Esteban Lopez sold 2,000 shares of the business's stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $67.42, for a transaction totalling $134,840.00. Following the completion of the sale, the director now directly owns 3,600 shares of the company's stock, valued at $242,712. Learn More on Esteban Lopez's trading history.
Who are Axonics' active insiders?: Axonics' insider roster includes Juliet Bakker (Director), Raymond Cohen (CEO), Danny Dearen (Insider), Alfred Ford, Jr. (Insider), Kari Keese (CFO), Jane Kiernan (Director), Esteban Lopez (Director), Robert Mcnamara (Director), Karen Noblett (Insider), Rinda Sama (COO), and John Woock (CMO). Learn More on Axonics' active insiders.
Are insiders buying or selling shares of Axonics?: During the last year, insiders at the sold shares 11 times. They sold a total of 121,779 shares worth more than $7,915,525.91. The most recent insider tranaction occured on January, 31st when insider Karen Noblett sold 11,288 shares worth more than $764,649.12. Insiders at Axonics own 1.9% of the company. Learn More about insider trades at Axonics.
Information on this page was last updated on 1/31/2024.

Esteban Lopez Insider Trading History at Axonics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/13/2022	Sell	2,000	$67.42	$134,840.00	3,600

Esteban Lopez Buying and Selling Activity at Axonics

Axonics Company Overview

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Today's Range

Now: $66.69

$66.50

$66.88

50 Day Range

MA: $67.90

$66.47

$69.65

2 Week Range

Now: $66.69

$47.59

$69.68

Volume

318,433 shs

Average Volume

921,149 shs

Market Capitalization

$3.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

The Gold Grab of the Century

From Colonial Metals | Ad